CMB International Securities | Equity Research | Company Update



招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

Ping An (2318 HK)

Life business reform to continue into 2H

Ping An's 1H20 group operating profit +1.2% YoY to RMB 74.3bn, while net profit decreased 29.7% YoY to RMB 68.7bn, including impact of discount rate change (~RMB 3.7bn) and short-term investment variances (~RMB 2bn). Most business lines suffered from market headwinds in time of COVID-19. Life insurance reform, which the Company embarked on since the end of 2018, also weighed on short run performance. Since the life business reform is about to be completed by year end, next year will likely witness substantial growth.

- Life business continue to be under pressure. Life business missed expectation. NBV of life and health insurance declined 24.4% YoY, among which agent channel NBV declined 23.5% YoY. NBV margin decreased 8ppt YoY to 36.7% (agent channel NBV margin -3.7ppt). Agent team building also remained challenging. Limited activities of agents in 1H20 also dragged persistency ratio of policies and renewal premium collection.
- Result positives. 1) P&C achieved premium growth of 10.5% against market headwinds (auto +3.6%, non-auto +26.4%); 2) Number of life insurance agents recovered 1.2% QoQ in 2Q to 1,145 thousand., suggesting stabilization of agent team. 3) Interim dividend increased to RMB 0.8 per share, +6.9% YoY and representing 19.6% of 1H20 attributable operating profit (18.6% in 1H19). This signals the Company's increasing willingness to share returns with shareholders.
- Other result negatives. 1) Operating profit posted negative growth in 1H20 for P&C, banking, trust business and etc.; 2) EV growth less than expected due to lackluster NBV growth, negative investment return variances and fewer operating variances due to decrease in persistency ratio. 3) Combined ratio of P&C insurance rose to 98.1%, up 1.5ppt YoY.
- Catalysts. 1) Life insurance business recovery; 2) Future listing of Lufax.
- **Risks.** 1) Life insurance reform progress slower than expected; 2) Worsening of P&C underwriting margin.
- Valuation. We lower major forecasts for NBV, EV, net profit and etc. to reflect weaker-than-expected 1H20 results. We trim TP to HK\$ 92.67 accordingly based on SOTP method. Given expected dividend yield of 3.0% in 2020, potential return is 14.2%. Maintain BUY.

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
GWP (RMB mn)	719,556	795,064	822,431	881,893	944,984
YoY growth (%)	18.9%	10.5%	3.4%	7.2%	7.2%
Net profit (RMB mn)	107,404	149,407	135,638	150,238	164,930
EPS (RMB)	6.02	8.41	7.63	8.46	9.28
YoY growth (%)	31.1	39.6	-9.2	10.8	9.8
Consensus EPS (RMB)	n.a.	n.a.	7.47	8.74	10.10
P/E (x)	12.1	8.7	9.8	8.8	8.1
P/B (x)	2.4	2.0	1.7	1.5	1.3
P/EV (x)	1.3	1.1	1.0	0.9	0.8
Yield (%)	2.4%	2.8%	3.0%	3.3%	3.6%
ROE (%)	20.9%	24.3%	18.5%	17.6%	16.7%

Source: Company data, Bloomberg, CMBIS

BUY (Maintain)

Target Price HK\$92.67 (Previous TP HK\$96.06)
Up/Downside +11.2%
Current Price HK\$83.3

China Insurance Sector

Wenjie Ding, PhD

(852) 3900 0856/(86) 755 2367 5597 dingwenjie@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	1,569,586
Avg 3 mths t/o (HK\$ mn)	2,817.60
52w High/Low (HK\$)	99.18/67.76
Total Issued Shares (mn)	7,488 (H)
, ,	10,833 (A)

Source: Bloomberg

Shareholding Structure

Charoen Pokphand Group	9.04%
Shenzhen Investment Holdings	5.27%

Source: HKEx

Share Performance

	Absolute	Relative
1-mth	0.4%	-2.2%
3-mth	8.9%	-0.9%
6-mth	-2.1%	0.6%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: PwC

Related Reports

- . "Explore the boundless" 4 Aug 2020 (initiation report)
- 2. "Senior management change" 28 Oct 2019
- 3. "Steady growth in operating profit"– 19 Aug 2019



Focus Charts

Figure 1: Results summary

RMB mn			
P&L	1H20	1H19	YoY
Gross written premiums	445,505	446,481	-0.2%
Net earned premiums	415,754	421,432	-1.3%
Reinsurance income	3,400	3,667	-7.3%
Reinsurance commission income	3,400	3,667	-7.3%
Interest income from banking operations	94,669	86,583	9.3%
Fees and commission income from non-insurance operations	29,488	26,861	9.8%
Interest revenue from non-banking operations	56,288	49,402	13.9%
Dividend income, realized & unrealized gains	44,629	61,659	-27.6%
Share of profits from associates and JVs	8,007	12,164	-34.2%
Other income	31,045	28,478	9.0%
Total income	675,273	678,082	-0.4%
Claims and policyholders' benefits	(330,289)	(325,736)	1.4%
Commission expenses on insurance operations	(57,354)	(61,657)	-7.0%
Interest expenses on banking operations	(44,264)	(42,827)	3.4%
Fees and commission expenses on non-insurance operations	(5,650)	(4,850)	16.5%
Net impairment losses on financial assets	(40,526)	(30,003)	35.1%
Other impairment losses on other assets	(1,760)	(979)	79.8%
Foreign exchange gains	140	457	-69.4%
General and administrative expenses	(83,337)	(83,054)	0.3%
Finance costs/Interest expenses on non-banking operations	(12,982)	(9,756)	33.1%
Other expenses	(16,498)	(15,602)	5.7%
Total expenses	(592,520)	(574,007)	3.2%
Pretax profit	90,760	116,239	-21.9%
Income tax	-14,792	-10,501	40.9%
Less: (Minorities)	-7,285	-8,062	-9.6%
Net profit attributable to shareholders	68,683	97,676	-29.7%
Operating profit attributable to shareholders	74,310	73,464	1.2%
B/S	1H20	2H19	YoY
Total assets	8,848,631	8,222,929	7.6%
Total liabilities	7,926,460	7,370,559	7.5%
Shareholder equity	701,972	673,161	4.3%
Key metric (during period)	1H20	1H19	YoY
New business value of L&H (RMB bn)	31,031	41,052	-24.4%
P&C written premiums (RMB bn)	144,118	130,466	10.5%
- Auto insurance premiums (RMB bn)	95,646	92,338	3.6%
Combined ratio of P&C	98.1%	96.6%	1.5 ppt
Net investment yield of insurance funds	4.1%	4.5%	-0.4 ppt
Total investment yield of insurance funds	4.5%	5.6%	-1.1 ppt

Source: Company data, CMBIS



Figure 2: Key operating metrics

		New			Old			Diff	
RMB mn	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
GWP	822,431	881,893	944,984	857,284	928,157	1,000,866	-4.1%	-5.0%	-5.6%
Net profit	135,638	150,238	164,930	150,257	171,180	192,182	-9.7%	-12.2%	-14.2%
New business value	62,932	68,128	71,652	69,295	75,218	80,075	-9.2%	-9.4%	-10.5%
NBV growth	-17.1%	8.3%	5.2%	-8.8%	8.5%	6.5%	-8.4 ppt	-0.3 ppt	-1.3 ppt
Group EV	1,370,106	1,553,209	1,750,485	1,383,030	1,576,073	1,784,540	-0.9%	-1.5%	-1.9%

Source: Company data, CMBIS estimates

Figure 3: Breakdown of operating profit

RMB mn	1H20	1H19	YoY
Life & Health insurance	51,127	47,958	6.6%
P&C insurance	8,234	9,990	-17.6%
Banking	7,927	8,934	-11.3%
Trust	1,651	1,871	-11.8%
Securities	1,509	1,199	25.9%
Other Asset management	2,671	3,913	-31.7%
Fintech & healthtech	3,438	2,802	22.7%
Others and elliminations	-2,247	-3,202	-29.8%
Group total	74,310	73,465	1.2%

Source: Company data, CMBIS

Figure 4: Valuation table

Life insurance	
3-year avg. ROEV	18.9%
Terminal growth rate	2%
Cost of equity	16.0%
Fair P/EV (x) for life insurance business	1.21
Life EV per share (at YE20, in RMB)	47.95
Value of Life insurance per share (in RMB)	57.88
P&C insurance	
3-year avg. ROE	20.0%
Fair P/B ratio for P&C business	1.29
P&C BVPS (at YE20, in RMB)	5.62
Value of P&C per share (in RMB)	7.23
Banking	
CMBI target price of PAB (in RMB)	19.8
PAB issued shares (million)	19,406
Ping An's sharehoidng in PAB	57.94%
Value of PAB per share (in RMB)	12.18
Asset management and others	
Fair P/B ratio	1.00
BVPS (at YE20, in RMB)	6.93
Value of AM business per share (in RMB)	6.93
Technology business	
Value of tech business per share (in RMB)	13.61
Sum of the above business segments (in RMB)	97.84
Conglomerate discount	15%
Target price (in RMB)	83.16
Target price (in HKD)	92.67

Source: Company data, CMBIS estimates



Financial Summary

Income statement						Key ratios					
YE 31 Dec (RMB mn) GWP & policy fees	FY18A 719,556	FY19E 795,064	FY20E 857,284	FY21E 928,157	FY22E 1,000,866	YE 31 Dec Group	FY18A	FY19E	FY20E	FY21E	FY22E
Net earned premiums	677,703	748,779	803,549	868,192	934,234	Net investment yield	5.2%	5.2%	5.4%	5.2%	5.2%
Reinsurance income	7,966	7,572	9,036	9,563	10,256	Total investment yield	3.7%	6.9%	6.0%	6.0%	5.8%
Total premium income	685,669	756,351	812,585	877,754	944,489	ROAE	20.9%	24.3%	20.4%	19.6%	18.8%
						ROAA	1.6%	1.9%	1.7%	1.8%	1.8%
Investment income	120,520	201,738	209,819	230,304	252,760	EV growth	21.5%	21.8%	13.3%	14.0%	13.2%
Net inv't income from banking	74,783	90,187	103,227	112,414	123,199	Group comprehensive solvency	216.4%	229.8%	228.4%	225.3%	222.4%
Net fees and commission income	37,191	44,230	61,819	68,870	76,929						
Claims and benefits	(439,596)	(578,313)	(614,286)	(660,793)	(707,796)	Life & Health insurance					
Commission expenses	(130,394)	(114,766)	(124,999)	(136,013)	(147,286)	GWP growth	21.5%	11.5%	6.0%	6.7%	6.2%
G&A expenses	(151,581)	(177,164)	(196,328)	(212,294)	(231,239)	Agency FYRP growth	-3.1%	-7.8%	-3.7%	7.7%	5.0%
Impairment loss	(53,814)	(67,266)	(71,198)	(76,172)	(81,640)	NBV growth	7.3%	5.1%	-8.8%	8.5%	6.5%
Other income and expenses	2,299	6,518	6,356	10,540	13,772	NBV margin of agency channel	57.1%	64.9%	61.8%	61.7%	61.7%
Associates/JVs	18,074	23,224	24,832	26,678	28,291	L&H EV growth	23.5%	23.5%	17.4%	15.9%	14.9%
Pretax profit	163,151	184,739	211,827	241,289	271,480	L&H operating ROEV	30.8%	25.0%	20.3%	19.4%	18.5%
						P&C insurance					
Tax	(42,699)	(20,374)	(44,733)	(50,608)	(56,663)	GWP growth	14.5%	9.5%	10.2%	11.2%	10.7%
Less: minorities	(13,048)	(14,958)	(16,836)	(19,501)	(22,635)	Combined ratio	96.0%	96.4%	95.9%	96.2%	96.3%
Net profit	107,404	149,407	150,257	171,180	192,182						
						Profit breakdown					
						Life & health insurance	62%	66%	67%	65%	64%
Balance sheet						P&C insurance	11%	16%	16%	15%	15%
YE 31 Dec (RMB mn)	FY18A	FY19E	FY20E	FY21E	FY22E	Banking	13%	12%	12%	13%	13%
Investment assets	4,056,704	4,659,117	5,225,641	5,815,960	6,477,061	Others	14%	6%	5%	7%	8%
Loans to customers	1,929,842	2,240,396	2,457,308	2,727,612	3,027,650						
Total assets	7,142,960	8,222,929	9,085,927	10,037,79	11,105,02	Per share data					
Insurance contract liabilities	2,264,634	2,669,673	3,041,297	3,419,217	3,826,357	EPS (RMB)	6.02	8.41	8.46	9.63	10.82
Customer deposits	2,114,344	2,431,713	2,730,342	3,030,680	3,364,055	DPS (RMB)	1.72	2.04	2.47	2.81	3.15
Total liabilities	6,459,317	7,370,559	8,071,079	8,845,048	9,711,619	BVPS (RMB)	30.44	36.82	43.84	51.53	60.20
Shareholders' equity	556,508	673,161	801,479	941,975	1,100,447	EVPS (RMB)	54.84	65.67	75.66	86.22	97.62

Source: Company data, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc..) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.